gefitinib has been researched along with tamoxifen in 46 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (tamoxifen) | Trials (tamoxifen) | Recent Studies (post-2010) (tamoxifen) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 20,630 | 2,227 | 6,256 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 21 (45.65) | 29.6817 |
| 2010's | 23 (50.00) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Choowongkomon, K; Gleeson, MP; Hannongbua, S; Suphakun, P; Toviwek, B | 1 |
| Capuzzi, SJ; Fisher, EG; García-Sastre, A; He, S; Li, H; Martínez-Romero, C; Muratov, EN; Qiu, X; Shinn, P; Sun, W; Tawa, G; Tropsha, A; Xu, M; Zheng, W; Zhu, W | 1 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; Madden, T; Nicholson, RI; Wakeling, AE | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Hayes, DF | 1 |
| Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H | 1 |
| Barrow, D; Dutkowskil, C; Hiscox, S; Morgan, L; Nicholson, RI; Wakeling, A | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV | 1 |
| Eicke, N; Emons, G; Gründker, C; Günthert, AR; Läsche, J; Olota, A | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Barrow, D; Gee, J; Green, TP; Hiscox, S; Morgan, L; Nicholson, RI | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| du Bois, A; Gropp, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Meier, W; Pfisterer, J; Schmalfeldt, B; Sehouli, J; Stähle, A; Wagner, U | 1 |
| Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M | 1 |
| Barrow, D; Ellis, IO; Gee, JM; Hiscox, SE; Hutcheson, IR; Knowlden, JM; Nicholson, RI; Robertson, JF | 1 |
| Horn, F; Klappenberger, S; Lattrich, C; Ortmann, O; Pfeiler, G; Treeck, O | 1 |
| Creighton, CJ; Huang, S; Massarweh, S; Osborne, CK; Qin, L; Rimawi, M; Schiff, R; Tsimelzon, A; Weiss, H | 1 |
| Hamburger, AW | 1 |
| Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A | 1 |
| Agrawal, A; Cheung, KL; Gee, J; Gutteridge, E; Nicholson, R; Robertson, J | 1 |
| Gao, W; Shen, H; Shu, YQ; Sun, J; Yuan, Y | 1 |
| Anagnostou, VK; Dirix, LY; Gutierrez, C; Mackey, JR; Magill, P; Migliaccio, I; Neven, P; Osborne, CK; Rimm, DL; Robert, J; Schiff, R; Sellers, M; Underhill, C | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L | 1 |
| Emsley, P; Turnbull, AP | 1 |
| Bally, MB; Donohue, E; Dragowska, WH; Gelmon, KA; Gorski, SM; Kapanen, AI; Qadir, MA; Rawji, JS; Roberge, M; Wang, JC; Warburton, C; Weppler, SA; Wong, LY | 1 |
| Mehta, A; Tripathy, D | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Dong, W; Fang, S; Li, C; Li, M; Liu, J; Song, B; Tang, B; Wang, Z; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Chang, SM; Chen, LH; Chen, TS; Chiu, KL; Liu, CM; Ma, WL; Ni, YL; Sher, YP; Yang, SY; Yu, SL | 1 |
| Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Cunha, SI; Jia, M; Souchelnytskyi, S | 1 |
| Abdelmalek, CM; Gehringer, M; Hesse, SS; Hu, Z; Kinnen, FJM; Kronenberger, T; Küblbeck, J; Kudolo, M; Laufer, SA; Malik, A; Niess, R; Witt-Enderby, PA; Zender, L; Zlotos, DP | 1 |
| Acconcia, F | 1 |
5 review(s) available for gefitinib and tamoxifen
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gefitinib; Humans; Membrane Glycoproteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; RNA-Binding Proteins; Tamoxifen; Ubiquitin-Protein Ligases | 2008 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
5 trial(s) available for gefitinib and tamoxifen
| Article | Year |
|---|---|
A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Biological Availability; Drug Combinations; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Quinazolines; Tamoxifen; Taxoids | 2007 |
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2010 |
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Treatment Outcome | 2011 |
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tamoxifen | 2015 |
36 other study(ies) available for gefitinib and tamoxifen
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Synthesis and evaluation of the NSCLC anti-cancer activity and physical properties of 4-aryl-N-phenylpyrimidin-2-amines.
Topics: A549 Cells; Amines; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Humans; Lung Neoplasms; Pyrimidines; Solubility; Structure-Activity Relationship; Sulfonamides | 2017 |
Computer-Aided Discovery and Characterization of Novel Ebola Virus Inhibitors.
Topics: Animals; Antiviral Agents; Chlorocebus aethiops; Drug Discovery; Drug Evaluation, Preclinical; Ebolavirus; HeLa Cells; Humans; Molecular Structure; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Virus Internalization | 2018 |
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured | 2002 |
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured | 2003 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
Tamoxifen: Dr. Jekyll and Mr. Hyde?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Trastuzumab | 2004 |
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estrogen Receptor Modulators; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transplantation, Heterologous; Up-Regulation | 2004 |
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Phenotype; Quinazolines; Tamoxifen | 2004 |
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Phosphorylation; Quinazolines; Signal Transduction; Tamoxifen; Triptorelin Pamoate | 2005 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Focal Adhesion Kinase 1; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Paxillin; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; Tamoxifen | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neuregulin-1; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen; Trastuzumab | 2007 |
Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression.
Topics: Antineoplastic Agents; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Estrogen Antagonists; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tamoxifen | 2007 |
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transcription, Genetic; Xenograft Model Antitumor Assays | 2008 |
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays | 2008 |
Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Estrogen Receptor beta; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tamoxifen | 2010 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 2012 |
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Studying protein-ligand interactions using X-ray crystallography.
Topics: Binding Sites; Crystallization; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Molecular Docking Simulation; Neoplasm Proteins; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Software; Tamoxifen | 2013 |
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Cadaverine; Cell Line, Tumor; Cell Survival; Cytoplasmic Vesicles; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Gene Silencing; Humans; Hydroxychloroquine; Membrane Proteins; Mice; Phagosomes; Quinazolines; RNA, Small Interfering; Signal Transduction; Staining and Labeling; Tamoxifen; Treatment Outcome; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; RNA, Messenger; Signal Transduction; Tamoxifen; Up-Regulation | 2015 |
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolines; Receptor, ErbB-2; Tamoxifen | 2015 |
Exposure to EGF and 17β‑estradiol irreversibly affects the proliferation and transformation of MCF7 cells but is not sufficient to promote tumor growth in a xenograft mouse model upon withdrawal of exposure.
Topics: Animals; Benzamides; Carcinogenesis; Cell Proliferation; Cell Transformation, Neoplastic; Dioxoles; Epidermal Growth Factor; Estradiol; Female; Gefitinib; Humans; MCF-7 Cells; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Phenotype; Quinazolines; Spheroids, Cellular; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |
Gefitinib-Tamoxifen Hybrid Ligands as Potent Agents against Triple-Negative Breast Cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Tamoxifen; Triple Negative Breast Neoplasms | 2022 |
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen | 2022 |